Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for metabolic genetic diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Novato, CA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol RARE. Ultragenyx initially filed confidentially on October 4, 2013. J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.
